TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27793181
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy (ICBT) programme FearFighter™, nine sessions with weekly telephone contact
Study: 27793181
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy (ICBT) programme FearFighter™
Study: 17869296
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg vardenafil in patients with ASIA classification A and spinal cord injury above T6
Study: 3109142
Drug: Nisoldipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (20 mg orally t.i.d. for 3 patients, 20 mg b.i.d. for 5 patients)
Study: 3109142
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg orally t.i.d.)
Study: 29636355
Drug: Treatment-as-usual control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual control (n=60)
Study: 28768069
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO₂) at 1.5 ATA for 60 minutes daily for 40 sessions
Study: 28768069
Drug: Sham chamber
Normalized name: HOLDING CHAMBER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham chamber sessions at 1.2 ATA, air for 60 minutes daily for 40 sessions
Study: 25179788
Drug: Plerixafor (MZ)
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor (MZ) given as a single dose to 30 poor mobilizers (PM)
Study: 25179788
Drug: G‐CSF +
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF + Plerixafor (MZ)
Study: 22455385
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% oxytetracycline hydrochloride three times a day for 1 week
Study: 10634964
Drug: Micronised fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fenofibrate 200 mg daily
Study: 3529953
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin (325 mg)
Study: 28089180
Drug: Plain aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain aspirin (325 mg)
Study: 2037955
Drug: Metronidazole treatment
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole treatment (250 mg tid for 7 days) plus debridement
Study: 2037955
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment plus debridement (positive control)
Study: 2037955
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (positive control)
Study: 6786566
Drug: Branded analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded analgesic tablets
Study: 6786566
Drug: Unbranded analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unbranded analgesic tablets
Study: 6786566
Drug: Placebo (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inert formulation)
Study: 6786566
Drug: Active formulation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active formulation (branded)
Study: 31426749
Drug: ezetimibe/simvastatin 10/10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/10 mg
Study: 31426749
Drug: rosuvastatin 10 mg
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin 10 mg
Study: 28337563
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) combined with facial exercise treatment
Study: 28337563
Drug: Facial exercise
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Facial exercise treatment alone
Study: 21867390
Drug: Enoxaparin 20
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 20 mg/0.2 ml subcutaneous (sc) 2 hr before surgery
Study: 17760592
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with 5-aminolevulinic acid or indocyanine green
Study: 17760592
Drug: New procedural
Approvals — FDA: no, EMA: no, PMDA: no
Description: New procedural therapies (radiofrequency, light or laser, photodynamic therapy)
Study: 15500555
Drug: 5 MU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU daily of IFN alfa‐2b for 4 weeks followed by IFN (5 MU TIW) plus ribavirin (1000/1200 mg/daily) for 48 weeks (group 1)
Study: 15500555
Drug: 5 MU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU TIW of IFN alfa 2b for 4 weeks followed by IFN (5 MU TIW) plus ribavirin (1000/1200 mg/daily) for 48 weeks (group 2)
Study: 11256836
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen blockade with UFT (400 mg/day)
Study: 10352494
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) therapy for 3 months
Study: 10352494
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in FEV1% between baseline and post-treatment
Study: 7655780
Drug: IL-2 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 (3 x 10(6) IU/day subcutaneously for 4 weeks) plus melatonin (40 mg/day orally)
Study: 29624832
Drug: Metacognitive Interpersonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive Interpersonal Therapy (MIT-G)
Study: 29624832
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list + Treatment as Usual (TAU)
Study: 28467116
Drug: Combined self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined self-administered foot massage and CBT
Study: 25599690
Drug: Combined strategy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined strategy intervention including printed information, treatment-compliance check cards, and text messages.
Study: 16153217
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 or 20 mg
Study: 14690014
Drug: Levamisole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (80 mg every other day for 6 weeks) + rifampicin (600 mg/day) + doxycycline (200 mg/day) for 6 weeks
Study: 14690014
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rifampicin 600 mg/day + doxycycline 200 mg/day for 6 weeks)
Study: 2069382
Drug: Loracarbef (LY163892)
Normalized name: Loracarbef
DrugBank: Loracarbef (DB00447)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loracarbef (LY163892) at 200 mg once daily (n = 53)
Study: 2069382
Drug: Cefaclor at
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor at 250 mg three times daily (n = 55)
Study: 26931369
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and capecitabine combination chemotherapy with sequential telomerase GV1001 vaccine (n=18)
Study: 26931369
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and capecitabine combination chemotherapy with concomitant telomerase GV1001 vaccine (n=24)
Study: 26931369
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and capecitabine combination chemotherapy
Study: 22905596
Drug: High-dose hypoallergenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hypoallergenic 6-grass pollen preparation (SCIT)
Study: 17097812
Drug: Patients 1
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients 1 year after treatment initiation
Study: 9366459
Drug: 0.25 microg
Normalized name: calcitriol 0.25 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 microg x kg(‐1) x h(‐1) naloxone (low dose)
Study: 9366459
Drug: 1 microg
Normalized name: Alpha 1 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microg x kg(‐1) x h(‐1) naloxone (high dose)
Study: 30711295
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of dental implants with bar overdentures (n=35)
Study: 29537647
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE, 0.625 mg/day)
Study: 19155011
Drug: CEE (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE (0.625 mg/day) plus medroxyprogesterone acetate (MPA, 2.5mg/day)
Study: 15075543
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg, eight doses administered subcutaneously twice weekly beginning on day 4 of tuberculosis therapy
Study: 10021962
Drug: 27-G Quincke
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 27-G Quincke needle
Study: 10021962
Drug: 27-G Whitacre
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 27-G Whitacre needle
Study: 31841136
Drug: Continued bivalirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued bivalirudin infusion after PCI
Study: 31841136
Drug: No bivalirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bivalirudin infusion after PCI
Study: 21810165
Drug: Methylnaltrexone 12
Normalized name: methylnaltrexone 12 mg/0.6 mL subcutaneous kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone 12 mg subcutaneous daily for 4 weeks
Study: 16686911
Drug: Triptan treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptan treatment
Study: 15560164
Drug: Efferent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efferent therapy after medication and photomodification of the blood
Study: 12670352
Drug: Desferrioxamine (DFX)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desferrioxamine (DFX) alone (40‐50 mg/kg/d s.c. over 8‐12 h, five times weekly)
Study: 12670352
Drug: Combined DFX
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined DFX twice weekly and deferiprone (75 mg/kg/d)
Study: 22385038
Drug: MicroPlaSter alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: MicroPlaSter alpha device (2 min cold atmospheric argon plasma treatment)
Study: 22385038
Drug: MicroPlaSter beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MicroPlaSter beta device (2 min cold atmospheric argon plasma treatment)
Study: 20332772
Drug: Venlafaxine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (75 mg hora somni)
Study: 18329226
Drug: Gay-specific cognitive-behavioral
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gay-specific cognitive-behavioral therapy (GCBT, n = 64)
Study: 18329226
Drug: Gay-specific social
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gay-specific social support therapy (GSST, n = 64)
Study: 16143248
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg)
Study: 12756512
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg daidzein twice daily for 10 days
Study: 10051505
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) therapy with steroid priming
Study: 8595083
Drug: Pyridoxine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (5 mg/kg body weight/day) for 4 weeks
Study: 1709446
Drug: Single infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single infusion of gamma globulin (2 g/kg over 10 hours)
Study: 1709446
Drug: Four daily
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four daily infusions of gamma globulin (400 mg/kg for four consecutive days)
Study: 1709446
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (single infusion and four daily infusions)
Study: 7027425
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d antrafenine
Study: 7027425
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d aspirin
Study: 21649457
Drug: Decaffeinated green
Normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated green tea extract (GTE) 1,500 mg daily for 16 weeks
Study: 19234815
Drug: Midazolam, 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam, 0.025 mg x kg(‐1)
Study: 16720593
Drug: Statin use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin use with >1 defined daily dose
Study: 16720593
Drug: Statin use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin use with >2 defined daily doses
Study: 15448611
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg levobupivacaine with 25 microg fentanyl
Study: 15448611
Drug: Half the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half the dose of levobupivacaine and fentanyl (1.25 mg levobupivacaine with 12.5 microg fentanyl)
Study: 11268266
Drug: gemfibrozil, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil, 1200 mg/d (n = 1264)
Study: 9495299
Drug: FGF‐I (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF‐I (0.01 mg/kg body weight)
Study: 2567793
Drug: Loxiglumide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (oral administration, 800 mg three times daily for 7 days)
Study: 2567793
Drug: Loxiglumide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (oral administration, 30 min before test meal)
Study: 107583
Drug: Continuous sodium
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sodium fluoride treatment
Study: 107583
Drug: Intermittent sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sodium fluoride treatment
Study: 30774322
Drug: Higher-dose physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose physical activity (180 minutes/week)
Study: 30774322
Drug: Lower-dose physical
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose physical activity (120 minutes/week)
Study: 24433249
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for insomnia (CBT‐I) consisting of sleep restriction, psychoeducation about sleep, stabilization of the circadian rhythm, and challenging and correcting sleep state misperception, in three to eight sessions.
Study: 24433249
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) consisting of pharmacological and supportive psychosocial treatment.
Study: 18668363
Drug: E-T-CMF (epirubicin-alkylator
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-T-CMF (epirubicin-alkylator based adjuvant chemotherapy with paclitaxel)
Study: 18668363
Drug: E-CMF (epirubicin-alkylator
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-CMF (epirubicin-alkylator based adjuvant chemotherapy without paclitaxel)
Study: 25963190
Drug: Adjuvant hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormone therapy
Study: 14989560
Drug: Granulocyte/macrophage colony
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte/macrophage colony stimulating factor (GM-CSF) at a dose of 10 microg/kg for 14 days
Study: 10752807
Drug: BB-882 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: BB-882 (4 mg loading dose on the first day, followed by 96 mg/24 hrs for up to 120 hrs)
Study: 1403212
Drug: Two sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sequential reminder letters offering free influenza immunization without an appointment
Study: 3890666
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% dexamethasone drops
Study: 28953447
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance therapy (375 mg/m² every 2 months for 3 years)
Study: 15966464
Drug: SPP301 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPP301 5 mg
Study: 14681342
Drug: SPP301 >20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPP301 >20 mg
Study: 14681342
Drug: SPP301 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPP301 50 mg
Study: 14681342
Drug: SPP301 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPP301 100 mg
Study: 15966464
Drug: SPP301 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPP301 (all doses)
Study: 9443526
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg i.v. naloxone
Study: 8494665
Drug: Cephradine 500
Normalized name: cephradine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephradine 500 mg twice daily for 5 days
Study: 8494665
Drug: Amoxycillin 250
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 250 mg three times daily for 5 days
Study: 8494665
Drug: Phenoxymethylpenicillin 250
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin 250 mg four times daily for 5 days
Study: 30161291
Drug: GSK2618960 (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2618960 (0.6 mg kg–1)
Study: 30161291
Drug: GSK2618960 (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2618960 (2.0 mg kg–1)
Study: 25907945
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg celecoxib (group A)
Study: 25907945
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg Sou‐Medrol (group B)
Study: 21715516
Drug: Adequate-dairy (AD)
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate-dairy (AD) diet (3.5 daily servings)
Study: 21715516
Drug: Low-dairy (LD)
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dairy (LD) diet (<0.5 daily servings)
Study: 19340462
Drug: Gelatine sponge
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatine sponge soaked with a 10 mg morphine hydrochloride solution placed in the iliac region for local opiate therapy.
Study: 19340462
Drug: Intraoperatively centrally
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperatively centrally administered opiates injected into the contralateral gluteus maximus muscle for systemic therapy.
Study: 14504943
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (BC) supplementation (60 g day(‐1))
Study: 8150110
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human FSH (150 IU, SC, multiple doses)
Study: 25817472
Drug: Midwife group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midwife group (misoprostol treatment)
Study: 25817472
Drug: Physician group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician group (misoprostol treatment)
Study: 17031012
Drug: RRR-alpha-tocopherol 100
Normalized name: RRR-alpha-tocopheryl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopherol 100 mg/day
Study: 17031012
Drug: RRR-alpha-tocopherol 400
Normalized name: RRR-alpha-tocopheryl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopherol 400 mg/day
Study: 17031012
Drug: RRR-alpha-tocopherol 200
Normalized name: RRR-alpha-tocopheryl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopherol 200 mg/day
Study: 10676922
Drug: Limited prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Limited prednisone treatment followed by WinRho SDF (anti-D) therapy
Study: 8668663
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of FK506
Study: 8668663
Drug: Intravenous dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose of FK506
Study: 1979009
Drug: Doxacurium 0.037
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxacurium 0.037 mg kg‐1
Study: 1979009
Drug: Doxacurium 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxacurium 0.075 mg kg‐1
Study: 1979009
Drug: Vecuronium 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.075 mg kg‐1
Study: 1979009
Drug: Pancuronium 0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.09 mg kg‐1
Study: 1979009
Drug: High-dose doxacurium
Normalized name: Doxacurium
DrugBank: Doxacurium (DB01135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose doxacurium 0.075 mg kg‐1
Study: 31142474
Drug: Tocilizumab (TOC)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TOC) monotherapy
Study: 21642603
Drug: Diluted 4.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted 4.2% sodium bicarbonate (50 mL)
Study: 21642603
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline (50 mL)
Study: 19202222
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with pegylated interferon and ribavirin in group I (relapsers)
Study: 19202222
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with pegylated interferon and ribavirin in group II (non responders, partial responders, breakthrough non responders)
Study: 21711479
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg on demand
Study: 17227498
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg three times per week